Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30368396 | 0.97 | LMNA (0.56) | NPC1LMNARAB9ACRBNMAPT | |
| SCHEMBL30368405 | 0.95 | LMNA (0.55) | NPC1LMNARAB9ACRBNMAPT | |
| SCHEMBL30368533 | 0.95 | LMNA (0.55) | NPC1LMNARAB9ACRBNMAPT | |
| SCHEMBL30368319 | 0.94 | MAPT (0.54) | NPC1LMNARAB9ACRBNMAPT | |
| SCHEMBL25377740 | 0.87 | LMNA (0.47) | NPC1LMNARAB9ACRBNMAOA | |
| SCHEMBL30368557 | 0.87 | MAPT (0.52) | NPC1LMNAMAPTGAAMAOA | |
| SCHEMBL25375685 | 0.86 | LMNA (0.46) | NPC1LMNARAB9AMAPTPKM | |
| SCHEMBL25377108 | 0.86 | LMNA (0.46) | NPC1LMNARAB9ACRBNS1PR3 | |
| SCHEMBL25375125 | 0.86 | LMNA (0.46) | NPC1LMNARAB9AMAPTPKM | |
| SCHEMBL25376967 | 0.85 | S1PR3 (0.47) | NPC1LMNARAB9AS1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800634-B2 | ANTICANCER AGENTS | ICONIX PHARMACEUTICALS INC. | 2004-10-05 | — | — | US | disclosed |
| US-20030171390-A1 | Modulators of Rho C activity | ENTELOS HOLDING CORP. | 2003-09-11 | — | — | US | disclosed |
| WO-2003043582-A2 | MODULATORS OF RHO C ACTIVITY | ICONIX PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171390-A1 | Modulators of Rho C activity | RHOC, ARHGEF1, ROCK1 | NPC1 2115/4885LMNA 1790/4885RAB9A 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.